What does Epigral do?

Epigral Ltd manufactures and sells specialty chemicals, particularly Chlor Alkali and its derivatives, and operates in the mid-cap market with a market cap of Rs 7,714 Cr. As of March 2025, it reported net sales of 628 Cr and a net profit of 87 Cr.

Overview:<BR>Epigral Ltd is a company engaged in the manufacturing and selling of specialty chemicals, specifically Chlor Alkali and its derivatives, and operates within the mid-cap market.<BR><BR>History:<BR>Epigral Ltd was incorporated in 2007 as Meghmani Finechem Limited. The company underwent a status change when it was demerged from Meghmani Organics Limited as a going concern, effective May 10, 2021. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 628 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 87 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 7,714 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 22.00<BR>- Industry P/E: 47<BR>- Dividend Yield: 0.41%<BR>- Debt Equity: 0.26<BR>- Return on Equity: 18.78%<BR>- Price to Book: 4.05<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

When is the next results date for Epigral?

No Upcoming Board Meetings

Has Epigral declared dividend?

Epigral Ltd has declared a 25% dividend, amounting to $2.5 per share, with an ex-date of February 7, 2025. The dividend yield is 0.41%, and while the company has shown strong total returns over the past year and two years, it experienced negative returns in the last six months.

Epigral Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: 07 Feb 25<BR><BR>Dividend Yield: 0.41%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Epigral experienced a price return of -13.45%, a dividend return of 0.12%, resulting in a total return of -13.33%.<BR><BR>Over the past year, the company achieved a price return of 41.9%, with a dividend return of 0.57%, leading to a total return of 42.47%.<BR><BR>In the 2-year period, Epigral saw a price return of 64.87% and a dividend return of 0.87%, culminating in a total return of 65.74%.<BR><BR>For the 3-year period, the price return was 20.62%, the dividend return was 1.03%, resulting in a total return of 21.65%.<BR><BR>In the 4-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, Epigral reported no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, Epigral Ltd has declared a dividend and has shown strong total returns over the 1-year and 2-year periods, despite negative returns in the 6-month timeframe. The dividend yield indicates a modest return relative to the stock price, reflecting the company's commitment to returning value to shareholders.

Who are the peers of the Epigral?

Epigral's peers include Aether Industries, Elantas Beck, Privi Speciality, Galaxy Surfactants, Archean Chemical, Balaji Amines, Styrenix Performance, Camlin Fine, Laxmi Organic, and Neogen Chemicals. Styrenix Performance shows excellent management risk and growth, while Epigral has good management risk and capital structure, with a 1-year return of 22.51%.

Peers: The peers of Epigral are Aether Industri., Elantas Beck, Privi Speci., Galaxy Surfact., Archean Chemical, Balaji Amines, Styrenix Perfor., Camlin Fine, Laxmi Organic, and Neogen Chemicals.<BR><BR>Quality Snapshot: Excellent management risk is observed at Styrenix Perfor. and the rest. Good management risk is found at Elantas Beck, Galaxy Surfact., Archean Chemical, and Epigral. Average management risk is present at Privi Speci., Balaji Amines, Laxmi Organic, and Neogen Chemicals. Below Average management risk is noted at Aether Industri. and Camlin Fine. All peers exhibit Below Average growth except for Styrenix Perfor., which has Good growth, while the rest have Below Average growth. Capital Structure is Excellent for Aether Industri., Elantas Beck, Galaxy Surfact., Archean Chemical, Balaji Amines, and Laxmi Organic, while Epigral has Good capital structure, and Privi Speci. and Camlin Fine have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Camlin Fine at 141.62%, while the peer with the lowest is Aether Industri. at -9.58%. Epigral's 1-year return is 22.51%, which is significantly higher than Aether Industri. and lower than Camlin Fine. Additionally, Balaji Amines and Laxmi Organic have negative six-month returns.

Who are in the management team of Epigral?

As of March 2023, the management team of Epigral includes Chairman & Managing Director Maulik Jayantibhai Patel, Managing Director Kaushal Ashishbhai Soparkar, and several Executive and Independent Directors, totaling ten members with a diverse leadership structure.

As of March 2023, the management team of Epigral includes the following individuals:<BR><BR>1. Maulik Jayantibhai Patel - Chairman & Managing Director<BR>2. Kaushal Ashishbhai Soparkar - Managing Director<BR>3. Karana Rameshbhai Patel - Executive Director<BR>4. Ankit Natwarlal Patel - Executive Director<BR>5. Darshan Anandbhai Patel - Executive Director<BR>6. Manubhai Khodidas Patel - Independent Director<BR>7. NIRALI BHAVIN PARIKH - Independent Director<BR>8. Sanjay K Asher - Independent Director<BR>9. Kanubhai S Patel - Independent Director<BR>10. Raju Swamy - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, reflecting a diverse leadership structure within the company.

Who are the top shareholders of the Epigral?

The top shareholders of Epigral include Ashishbhai Natawarlal Soparkar with 14.65%, individual investors with 16.98%, mutual funds holding 4.48%, and foreign institutional investors at 3.01%. The largest public shareholder is HSBC Focused Fund with a 2.77% stake.

The top shareholders of Epigral include the promoters, who hold the majority of the shares. The promoter with the highest holding is Ashishbhai Natawarlal Soparkar, with a stake of 14.65%. Additionally, individual investors collectively hold 16.98% of the shares. Among institutional investors, mutual funds hold 4.48% through 8 schemes, while foreign institutional investors (FIIs) hold 3.01% across 83 entities. The highest public shareholder is HSBC Focused Fund, which has a holding of 2.77%.

How big is Epigral?

As of 24th July, Epigral Ltd has a market capitalization of 7,774.00 Cr, with recent net sales of 2,550.13 Cr and net profit of 357.69 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Epigral Ltd has a market capitalization of 7,774.00 Cr and is classified as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 2,550.13 Cr, while the sum of Net Profit for the same period is 357.69 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 1,904.53 Cr and Total Assets totaling 3,152.44 Cr.

Is Epigral overvalued or undervalued?

As of October 6, 2025, Epigral is fairly valued with a PE ratio of 17.25 and strong growth potential, making it a solid investment compared to peers like Solar Industries and Gujarat Fluoroch, despite recent underperformance against the Sensex.

As of 6 October 2025, the valuation grade for Epigral has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 17.25, an EV to EBITDA of 11.40, and a PEG ratio of 0.26, indicating strong growth potential relative to its price.<BR><BR>In comparison to its peers, Epigral's valuation appears reasonable, especially when contrasted with Solar Industries, which has a PE ratio of 101.44, and Gujarat Fluoroch at 64.03. Notably, Godrej Industries is considered attractive with a PE of 37.84, further highlighting Epigral's competitive positioning within the specialty chemicals sector. While Epigral's recent stock performance has lagged behind the Sensex over the past year, it remains a solid investment opportunity given its fair valuation and strong return on capital employed of 24.11%.

Is Epigral technically bullish or bearish?

As of 14 October 2025, Epigral's technical trend is bearish with moderate strength, indicated by bearish signals from the MACD, Bollinger Bands, and daily moving averages, despite mixed signals from the KST and a mildly bullish perspective from Dow Theory.

As of 14 October 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Epigral is bearish with moderate strength. Key indicators driving this stance include the weekly MACD and Bollinger Bands both indicating bearish conditions, along with daily moving averages also showing bearish signals. The KST presents a mixed view with a bearish weekly signal but a bullish monthly signal, while the Dow Theory suggests a mildly bullish weekly perspective. Overall, the bearish trend is reinforced by the stock's recent performance, underperforming the Sensex across multiple time frames.

Are Epigral latest results good or bad?

Epigral's latest results are concerning, showing a 68.12% decline in net profit quarter-on-quarter and a 37.00% drop year-on-year, alongside reduced revenue and compressed operating margins, indicating significant challenges for the company. The market has reacted negatively, with the stock trading 32.01% below its 52-week high.

Epigral's latest results are concerning, reflecting a significant decline in performance compared to previous quarters. In Q2 FY26, the company reported a net profit of ₹51.22 crores, which is a staggering 68.12% decrease quarter-on-quarter and a 37.00% drop year-on-year. This decline is accompanied by a reduction in revenue, which fell to ₹587.36 crores, down 3.16% from the previous quarter and 6.18% from the same quarter last year.<BR><BR>Additionally, the operating margin has compressed to 22.53%, down sharply from 26.94% in the previous quarter and significantly lower than the 28.50% margin a year ago. This margin compression raises questions about the sustainability of the company's profitability, especially as it faces rising interest costs, which surged by 286.41% year-on-year.<BR><BR>The market has reacted negatively, with the stock trading 32.01% below its 52-week high, indicating mounting concerns about the company's growth trajectory and operational efficiency. Overall, the results suggest that Epigral is currently facing significant challenges, making the latest performance appear quite bad.

Should I buy, sell or hold Epigral?

How has been the historical performance of Epigral?

Epigral has shown significant growth over the past five years, with net sales increasing from 828.60 Cr in Mar'21 to 2,550.13 Cr in Mar'25, and profit after tax rising from 100.84 Cr to 356.70 Cr. The company's total assets also grew from 1,448.70 Cr to 3,152.44 Cr, reflecting strong overall financial performance.

Answer:<BR>The historical performance of Epigral shows significant growth in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Epigral's net sales have increased from 828.60 Cr in Mar'21 to 2,550.13 Cr in Mar'25, demonstrating a strong upward trend. Total operating income followed a similar trajectory, rising from 828.60 Cr to 2,550.13 Cr during the same period. The company's total expenditure, excluding depreciation, also grew from 567.28 Cr in Mar'21 to 1,839.41 Cr in Mar'25, reflecting increased operational costs. Operating profit (PBDIT) has shown fluctuations, peaking at 725.93 Cr in Mar'25, while profit before tax reached 540.10 Cr, up from 160.86 Cr in Mar'21. Profit after tax has also risen significantly, from 100.84 Cr in Mar'21 to 356.70 Cr in Mar'25. The earnings per share (EPS) increased from 24.27 in Mar'21 to 82.91 in Mar'25, indicating improved profitability per share. On the balance sheet, total assets grew from 1,448.70 Cr in Mar'21 to 3,152.44 Cr in Mar'25, while total liabilities increased from 1,448.70 Cr to 3,152.44 Cr, showing a proportional rise in both assets and liabilities. Cash flow from operating activities improved from 229.00 Cr in Mar'21 to 440.00 Cr in Mar'25, contributing to a net cash inflow of 15.00 Cr in Mar'25, compared to an outflow of 11.00 Cr in Mar'24. Overall, Epigral has demonstrated robust growth in sales, profits, and asset base over the past five years.

Why is Epigral falling/rising?

As of 19-Dec, Epigral Ltd's stock price is at 1,400.00, reflecting a significant decline and underperformance compared to the Sensex. The stock has faced substantial losses over the past year and poor financial results, leading to negative investor sentiment.

As of 19-Dec, Epigral Ltd's stock price is falling, currently at 1,400.00, which reflects a decrease of 40.4 (-2.8%). The stock has recently hit a new 52-week low of Rs. 1376.9, indicating significant downward pressure. Over the past week, the stock has underperformed the Sensex, showing a decline of 1.06% compared to the benchmark's drop of only 0.40%. <BR><BR>In the last month, Epigral's stock has decreased by 4.58%, while the Sensex has only fallen by 0.30%. Year-to-date, the stock has experienced a substantial decline of 26.32%, contrasting sharply with the Sensex's gain of 8.69%. Over the past year, the stock has generated a return of -32.55%, significantly underperforming the Sensex, which has risen by 7.21%.<BR><BR>The company's financial performance has also contributed to the stock's decline. The operating profit has decreased at an annual rate of -5.49% over the last five years, and recent quarterly results showed a sharp decline in profit before tax and profit after tax, falling by 45.2% and 52.6%, respectively, compared to previous quarters. This poor performance, combined with the stock's long-term underperformance against broader market indices, has led to a negative sentiment among investors.<BR><BR>Despite some positive factors, such as high management efficiency and a strong ability to service debt, the overall outlook remains bleak due to the significant declines in both stock price and financial performance metrics. This combination of factors has resulted in the stock's current downward trajectory.

Which are the latest news on Epigral?